From: Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease
ILD(+)RA | UIP(+)RA | NSIP(+)RA | ||||||
---|---|---|---|---|---|---|---|---|
ILD(+)RA | UIP(+)RA | NSIP(+)RA | ILD(−)RA | P | P | P | ||
Number | 32 | 18 | 14 | 32 | ||||
Age | year | 70.2 (7.4) | 70.6 (8.0) | 69.6 (6.8) | 57.7 (13.8) | 0.0002 | 0.0013 | 0.0043 |
male number | n (%) | 11 (34.4) | 9 (50.0) | 2 (14.3) | 2 (6.3) | *0.0109 | *0.0007 | *0.5745 |
Disease duration | year | 15.5 (12.6) | 12.8 (12.2) | 18.9 (12.7) | 10.6 (7.4) | 0.1830 | 0.8953 | 0.0116 |
Steinbrocker stage III and IV | n (%) | 18 (56.3) | 9 (50.0) | 9 (64.3) | 21 (65.6) | *0.6088 | *0.3701 | *1.0000 |
Smoker or past smoker | n (%) | 10 (33.3) | 7 (38.9) | 3 (25.0) | 10 (32.3) | *1.0000 | *0.7581 | *0.7272 |
Rheumatoid factor positive | n (%) | 30 (93.8) | 17 (94.4) | 13 (92.9) | 27 (84.4) | *0.4258 | *0.3991 | *0.6506 |
Anti-citrullinated peptide antibody positive | n (%) | 31 (96.9) | 18 (100.0) | 13 (92.9) | 31 (96.9) | *1.0000 | *1.0000 | *0.5208 |
KL-6 | U/ml | 1096.4 (853.7) | 1086.2 (828.4) | 1108.8 (914.9) | 315.3 (257.9) | 2.44 × 10−7 | 2.97 × 10−6 | 0.0001 |
SP-D | ng/ml | 194.1 (244.7) | 177.3 (192.3) | 214.5 (303.0) | 46.0 (37.5) | 2.48 × 10−5 | 0.0008 | 0.0001 |
DAS28 | 4.0 (1.2) | 3.7 (1.3) | 4.3 (0.9) | 3.1 (1.2) | 0.0040 | 0.0793 | 0.0021 | |
DAS28-CRP | 3.0 (1.3) | 2.6 (1.4) | 3.4 (1.0) | 2.4 (1.0) | 0.0500 | 0.5855 | 0.0035 | |
NSAIDs administration | n (%) | 13 (41.9) | 7 (38.9) | 6 (46.2) | 15 (48.4) | *0.7989 | *0.5647 | *1.0000 |
Corticosteroid administration | n (%) | 26 (83.9) | 14 (77.8) | 12 (92.3) | 25 (80.6) | *1.0000 | *1.0000 | *0.6542 |
DMARDs administration | n (%) | 24 (77.4) | 14 (77.8) | 10 (76.9) | 30 (96.8) | *0.0529 | *0.0542 | *0.0706 |
sDMARDs administration | n (%) | 19 (61.3) | 11 (61.1) | 8 (61.5) | 19 (61.3) | *1.0000 | *1.0000 | *1.0000 |
bDMARDs administration | n (%) | 10 (32.3) | 5 (27.8) | 5 (38.5) | 22 (71.0) | *0.0048 | *0.0066 | *0.0874 |